Politico, April 29, 2016. We explain why the REGROW Act is an effort to short-circuit the FDA’s “gold standard” for drug approvals and why it shows “a lack of understanding of the importance of well-designed research.”
Read More »We’re In The News
As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.
Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.
Safety Groups Urge Government to Recall Ikea Dresser
Consumer Reports, April 27, 2016. Three deaths from falling furniture prompt urgent call for action from Consumer Reports and its partners.
Read More »Kids with ADHD Do Better with Therapy First, Study Finds
NBC News, April 27, 2016. National Center for Health Research weighs in on behavioral training programs for children with ADHD.
Read More »FDA Panel Votes Against Sarepta’s Drug for Duchenne Muscular Dystrophy
STAT, April 25, 2016. A federal advisory panel voted Monday that a drug from Sarepta Therapeutics was not effective for treating Duchenne muscular dystrophy, a rare and fatal muscle-wasting disease. About 13,000 children, mostly boys, are afflicted.
Read More »To Sway Drug Approval, Patient Advocates Turn up The Heat on the FDA
The Washington Post, April 23, 2016. Parents are desperate for a treatment for their sons with a rare disease, but if FDA approves a drug that isn’t proven to work, we are all at risk. FDA will meet to consider this dilemma on Monday, April 25.
Read More »